Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · FDC

FDC LIMITED

HealthcarePharmaceuticals & Biotechnology₹6087 cr market cap
₹378.05 ▲ +1.11% today As of 19 Nov 2026
52-week low ₹321.1052-week high ₹434.25

-13.9% from the 52-week high · +16.4% above the low

FDC Ltd. engages in the business of pharmaceutical. The company is headquartered in Mumbai, Maharashtra. The firm manufactures and distributes its range of generics, formulations and active pharmaceuticals at its manufacturing plants. The company also manufactures oral rehydration salts (ORS) and specialized formulations. The company has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. The company has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

The short version. FDC LIMITED reported revenue of ₹572 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹50 crore (up 78.6% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 69.66% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

FDC LIMITED trades 13.9% below its 52-week high and 16.4% above its 52-week low.

Change over period: —

1M+8.9%
3M+8.5%
6M+2.8%
1Y-8.7%

2 · The business

Is it growing?

Sales, year on year+20.9%

Sep 2026 revenue of ₹572 cr.

Profit, year on year+78.6%

Sep 2026 net profit of ₹50 cr.

Net margin8.7%

2.7 pts higher than a year earlier.

3-year growth13.2% profit

Revenue compounded at 7.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue572668585465473648492464
Net profit5013210328281213937
Net margin %8.719.817.76.16.018.77.98.1
EPS (₹)3.078.146.351.741.747.452.382.3

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue21712108194317841528133313441083
Net profit281267305194216301240174
Net margin %13.012.715.710.914.122.617.816.0
EPS (₹)17.2916.3918.7511.712.8117.8514.039.95

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.3% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.311.714.59.8
Return on capital %14.915.418.612.9
EBITDA margin %19.218.921.516.4
Net margin %12.312.114.910.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR7.6%9.8%
Profit CAGR13.2%-1.4%
Debt to equity0.00
Interest cover76.1x
Current ratio3.11
P/E ratio19.6

4 · The owners

Who holds it, and are they adding?

Promoter holding69.66%

Unchanged over 8 quarters.

Foreign institutions1.58%

Down 1.09 pts over 8 quarters.

Domestic institutions6.59%

Up 0.51 pts over 8 quarters.

Mutual fund schemes14

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter69.6669.6669.6669.6669.6669.6669.6669.660.0
FII2.672.552.412.432.322.41.41.58-1.09
DII6.086.377.176.826.276.296.316.59+0.51
Public21.5921.4220.7621.121.7521.6522.6322.17+0.58

Mutual fund holdings · Oct 2026

14 schemes hold this stock

12 the month before.

  • TATA INDIA PHARMA & HEALTHCARE FUND2.69% of NAV
  • ICICI Prudential ESG Exclusionary Strategy Fund1.62% of NAV
  • ICICI Prudential MNC Fund1.12% of NAV
  • ICICI Prudential Retirement Fund - Pure Equity Plan1.07% of NAV
  • ICICI Prudential Healthcare Fund0.71% of NAV
  • ICICI Prudential Small Cap Fund0.59% of NAV
  • NIPPON INDIA SMALL CAP FUND0.21% of NAV
  • ICICI Prudential Bharat Consumption Fund0.14% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for FDC LIMITED are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about FDC LIMITED

What is the FDC LIMITED share price?

FDC LIMITED (FDC) last closed at ₹378.05, up 1.11% on the day. Its 52-week range is ₹321.10 to ₹434.25.

What is the market cap of FDC LIMITED?

FDC LIMITED has a market capitalisation of about ₹6,087 crore. Its price-to-earnings ratio is 19.6.

How are FDC LIMITED's latest results?

FDC LIMITED reported revenue of ₹572 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹50 crore (up 78.6% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 69.66% in Sep 2026, up 0.00 points over 8 quarters.

Who owns FDC LIMITED?

As of Sep 2026, shareholding was: Promoter 69.66%, FII 1.58%, DII 6.59%, Public 22.17%.

How many mutual funds hold FDC LIMITED?

14 mutual fund schemes held FDC LIMITED in October 2026. That compares with 12 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 11 Feb 2026 · Interim Dividend - Rs. 5
  • 22 Nov 2024 · Interim Dividend - Rs. 5
  • 19 Mar 2020 · Interim Dividend - Rs. 0.8
  • 08 Aug 2017 · Dividend - Rs. 2.25
  • 17 Mar 2016 · Interim Dividend - Rs. 2.25
  • 23 Sep 2015 · Final Dividend - Rs. 2.25

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.